A detailed history of Asset Management One Co., Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Asset Management One Co., Ltd. holds 135,187 shares of VRTX stock, worth $67.9 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
135,187
Previous 133,760 1.07%
Holding current value
$67.9 Million
Previous $62.7 Million 0.28%
% of portfolio
0.23%
Previous 0.24%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$460.0 - $505.78 $656,420 - $721,748
1,427 Added 1.07%
135,187 $62.9 Million
Q2 2024

Jul 18, 2024

SELL
$392.81 - $485.53 $1.98 Million - $2.45 Million
-5,049 Reduced 3.64%
133,760 $62.7 Million
Q1 2024

May 02, 2024

SELL
$407.69 - $446.08 $1.57 Million - $1.72 Million
-3,848 Reduced 2.7%
138,809 $58 Million
Q4 2023

Jan 24, 2024

BUY
$343.0 - $410.68 $5.68 Million - $6.8 Million
16,559 Added 13.13%
142,657 $58 Million
Q3 2023

Oct 19, 2023

BUY
$338.18 - $362.46 $126,817 - $135,922
375 Added 0.3%
126,098 $43.8 Million
Q2 2023

Jul 31, 2023

SELL
$314.42 - $351.91 $374,159 - $418,772
-1,190 Reduced 0.94%
125,723 $44.2 Million
Q1 2023

Apr 25, 2023

BUY
$283.23 - $323.1 $2.26 Million - $2.58 Million
7,978 Added 6.71%
126,913 $40 Million
Q4 2022

Feb 06, 2023

SELL
$285.76 - $321.48 $2.04 Million - $2.29 Million
-7,130 Reduced 5.66%
118,935 $34.3 Million
Q3 2022

Nov 04, 2022

SELL
$273.83 - $305.53 $856,814 - $956,003
-3,129 Reduced 2.42%
126,065 $36.5 Million
Q2 2022

Jul 29, 2022

SELL
$234.96 - $292.55 $6.07 Million - $7.55 Million
-25,819 Reduced 16.66%
129,194 $36.4 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $3.39 Million - $4 Million
-15,309 Reduced 8.99%
155,013 $40.5 Million
Q4 2021

Feb 09, 2022

BUY
$177.01 - $223.45 $2.37 Million - $2.99 Million
13,382 Added 8.53%
170,322 $38 Million
Q3 2021

Nov 02, 2021

SELL
$181.39 - $202.99 $976,059 - $1.09 Million
-5,381 Reduced 3.32%
156,940 $28.5 Million
Q2 2021

Aug 03, 2021

BUY
$187.49 - $221.1 $900,139 - $1.06 Million
4,801 Added 3.05%
162,321 $32.7 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $448,612 - $522,918
-2,167 Reduced 1.36%
157,520 $33.8 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $4.48 Million - $5.98 Million
21,644 Added 15.68%
159,687 $37.3 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $1.03 Million - $1.22 Million
-4,034 Reduced 2.84%
138,043 $37.6 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $218,715 - $286,926
970 Added 0.69%
142,077 $41.2 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $65,724 - $81,529
-329 Reduced 0.23%
141,107 $33.6 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $95,024 - $127,628
570 Added 0.4%
141,436 $31 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $659,933 - $742,747
3,970 Added 2.9%
140,866 $23.9 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $1.94 Million - $2.24 Million
11,789 Added 9.42%
136,896 $25.1 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $47.8 Million - $56.9 Million
-292,016 Reduced 70.01%
125,107 $23 Million
Q4 2018

Feb 13, 2019

BUY
$151.91 - $192.21 $237,891 - $301,000
1,566 Added 0.38%
417,123 $69 Million
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $266,858 - $306,649
-1,591 Reduced 0.38%
415,557 $80 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $3.27 Million - $3.81 Million
22,425 Added 5.68%
417,148 $70.2 Million
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $752,845 - $879,627
4,966 Added 1.27%
394,723 $64.3 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $199,879 - $226,480
-1,456 Reduced 0.37%
389,757 $58.4 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $1.17 Million - $1.28 Million
7,896 Added 2.06%
391,213 $59.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
383,317
383,317 $49.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Asset Management One Co., Ltd. Portfolio

Follow Asset Management One Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management One Co., Ltd. with notifications on news.